New hope for tough prostate cancer: radioactive drug combo shows promise
NCT ID NCT05849298
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests a radioactive drug (lutetium-177) alone or combined with newer hormone therapy in 49 men with a specific type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread on regular scans. The goal is to see if the treatment can lower PSA levels and delay the spread of cancer. Participants must continue standard hormone therapy throughout the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Associated Med Professionals of NY
Syracuse, New York, 13210, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Novartis Investigative Site
São Paulo, São Paulo, 01308-050, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 05652-000, Brazil
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H2X 1R9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Olomouc, 779 00, Czechia
-
Novartis Investigative Site
Angers, 49055, France
-
Novartis Investigative Site
Brest, 29609, France
-
Novartis Investigative Site
Strasbourg, 67085, France
-
Novartis Investigative Site
Berlin, 10249, Germany
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Milan, MI, 20141, Italy
-
Novartis Investigative Site
Roma, RM, 00128, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Kielce, 25-640, Poland
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Oregon Urology Institute
Springfield, Oregon, 97477, United States
-
Rio Grande Urology
El Paso, Texas, 79912, United States
-
Rocky Mountain Cancer Centers
Denver, Colorado, 80218, United States
-
Unity Point Clinic
Des Moines, Iowa, 50323, United States
-
Univ of Texas Southwest Med Center
Dallas, Texas, 75390-9034, United States
-
University Cancer and Blood Center LLC
Athens, Georgia, 30607, United States
-
Urology Cancer Center PC
Omaha, Nebraska, 68130, United States
-
Urology Of Indiana
Indianapolis, Indiana, 46254, United States
-
Wellspan York Hospital
York, Pennsylvania, 17403, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo tame resistant prostate cancer?
- Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
- AI could predict which prostate cancers turn aggressive
- Triple imaging technique aims to sharpen prostate cancer detection
- New hope for hard-to-treat prostate cancer: drug combo trial launches
- New combo therapy aims to delay prostate cancer progression